Drug Database
Back to search

Poland· PL-100022725

Essentiale forte

A liver therapy product containing phospholipidum essentiale, registered in Poland by Opella Healthcare Poland Sp. z o.o.. The same ATC class is registered in 3 of our 19 countries.

ATC A05BA

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedEssentiale forteATCA05BAREGISTER NO.PL-100022725PACKS LISTED8CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about phospholipidum essentialeAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Phospholipidum essentiale is registered in 3 of 19 countries.

Countries holding a registration under ATC A05BA (liver therapy), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 3 of them publish a price we can compare per daily dose
Search phospholipidum essentiale products by name

Phospholipidum essentiale · ATC A05BA

3 / 19 countries

  • Belgiumprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Phospholipidum essentiale
Manufacturer
Opella Healthcare Poland Sp. z o.o.
Country
Poland (PL)
ATC code
A05BA
ATC class
Liver therapy
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 8

  • gtin
    05909990264711
  • gtin
    05909990264728
  • gtin
    05909990264735
  • gtin
    05909990264742
  • gtin
    05909990951505
  • gtin
    05902502339310
  • gtin
    05902502001033
  • gtin
    05904824391014

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same class

Other records under A05BA

Liver therapy, as other registers publish it.

All phospholipidum essentiale products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c415715e-3c9d-4e7f-bccd-c45800814b8e
GET /v1/drugs/c415715e-3c9d-4e7f-bccd-c45800814b8e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Kapsułki",
  "source": "urpl",
  "strength": "300 mg",
  "packaging": "05909990264711 ¦ OTC ¦ 1164\n50 kaps.\n05909990264728 ¦ OTC ¦ Skasowane ¦ 1165\n100 kaps.\n05909990264735 ¦ OTC ¦ Skasowane ¦ 1166\n250 kaps.\n05909990264742 ¦ OTC ¦ Skasowane ¦ 1168\n500 kaps.\n05909990951505 ¦ OTC ¦ 74104\n100 kaps.\n05902502339310 ¦ OTC ¦ 152946\n90 kaps.\n05902502001033 ¦ OTC ¦ 163340\n180 kaps.\n05904824391014 ¦ OTC ¦ 167827\n30 kaps.",
  "substance": "Fosfolipidy z nasion sojowych zawierające (3-sn-fosfatydylo)cholinę 300 mg",
  "common_name": "Phospholipidum essentiale",
  "pl_product_id": "100022725",
  "pozwolenie_nr": "02647",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about phospholipidum essentiale.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console